Melton's effort, involving a 30-person lab at Harvard and a startup company, Semma Therapeutics, which he named after his children, Sam and Emma, is one of the most costly and sustained efforts to turn stem cells into transplantable tissue, an attempt that Melton admits has been full of false starts and dead ends. “The public definitely doesn't appreciate that much of science is failure,” he says.
In fact, no field of biotechnology has promised more and delivered less in the way of treatments than embryonic stem cells.
Read Full Article »